Our findings further revealed one possible mechanism by which TSC achieved its therapeutic benefits among patients with mammary hyperplasia, implying that that TSC could prove a viable alternative in treating ERα-positive breast cancer patients. Here, ESR1 is linked to tuberous sclerosis.